Squarepoint Ops LLC Acquires New Shares in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Squarepoint Ops LLC acquired a new position in Vigil Neuroscience, Inc. (NASDAQ:VIGL) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 113,596 shares of the company’s stock, valued at approximately $193,000. Squarepoint Ops LLC owned approximately 0.28% of Vigil Neuroscience as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Two Sigma Advisers LP boosted its holdings in shares of Vigil Neuroscience by 243.8% during the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock valued at $117,000 after acquiring an additional 49,000 shares during the last quarter. Two Sigma Investments LP lifted its position in Vigil Neuroscience by 44.0% during the fourth quarter. Two Sigma Investments LP now owns 136,920 shares of the company’s stock valued at $233,000 after purchasing an additional 41,836 shares during the period. Trustees of Columbia University in the City of New York purchased a new stake in Vigil Neuroscience in the fourth quarter worth approximately $328,000. Millennium Management LLC grew its position in Vigil Neuroscience by 23.3% in the 4th quarter. Millennium Management LLC now owns 343,814 shares of the company’s stock worth $584,000 after purchasing an additional 65,058 shares during the period. Finally, Ensign Peak Advisors Inc grew its position in Vigil Neuroscience by 16.1% in the 4th quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company’s stock worth $1,195,000 after purchasing an additional 97,580 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. JMP Securities reissued a “market perform” rating on shares of Vigil Neuroscience in a report on Thursday, May 22nd. Citizens Jmp cut Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 22nd. HC Wainwright downgraded Vigil Neuroscience from a “buy” rating to a “neutral” rating and lowered their target price for the company from $14.00 to $8.00 in a report on Tuesday, May 27th. Jefferies Financial Group downgraded Vigil Neuroscience to a “hold” rating in a research note on Thursday, May 22nd. Finally, Citigroup lowered shares of Vigil Neuroscience to a “market perform” rating in a research report on Thursday, May 22nd. Ten investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $10.80.

Vigil Neuroscience Stock Performance

NASDAQ VIGL opened at $7.88 on Monday. The business’s fifty day moving average is $3.40 and its 200 day moving average is $2.61. Vigil Neuroscience, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $7.95. The company has a market capitalization of $367.78 million, a PE ratio of -3.83 and a beta of 3.43.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. On average, sell-side analysts forecast that Vigil Neuroscience, Inc. will post -2.07 EPS for the current year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.